Micro-Sphere partnership to further support the commercial needs of its customers
![](/46/pdcnewsitem/07/77/38/Micro-Sphere-partnership-to-further-support-the-commercial-needs-of-its-customers.jpg)
Customers will receive comprehensive support particularly at the critical phases of industrial scale-up, technology transfer and process validation.
Switzerland-based CDMO Micro-Sphere has announced its partnership with PTM Consulting, a leading provider of risk management and process optimisation solutions for the life sciences industry.
The two companies will join forces to offer customers comprehensive support across the entire drug product development and manufacturing cycle, particularly at the critical phases of industrial scale-up, technology transfer and process validation.
The partnership is part of Micro-Sphere’s drive to increase its service offer to support the commercial needs of its customers.
Micro-Sphere’s expertise in the set-up and optimisation of processes for spray-drying, mixing and capsule filling will be complemented by PTM’s knowledge of quality by design (QbD) and risk management principles, tools and statistics.
The collaboration announcement comes at a pivotal time for Micro-Sphere, which recently appointed a new CEO, Michael Grassberger, the company’s former head of business development.
In his new leadership role, he hopes to spearhead the growth of the CDMO’s commercial operations and see Micro-Sphere become the leading service provider for inhalable powder production through spray-drying and capsule filling.
Grassberger said: “The application of PTM methodology to Micro-Sphere’s processes will facilitate successful technology transfers, ensuring customers meet their desired quality target while minimising costs, time and wastage.
“With Micro-Sphere’s reputation already well-established for early-stage clinical supply, we look to make our mark in the commercial arena so we can fully support our customers for the entire drug development and manufacturing cycle. The collaboration with PTM is central to this vision.
“PTM’s risk-based project approach, deep regulatory knowledge and state-of-the-art statistical tools will strengthen our management of complex projects for our customers and supplement the existing skills and expertise on our team.”
The company also recently successfully completed its bi-annual Swissmedic inspection of its facility near Lugano, resulting in the renewal of its GMP approved status.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance